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This study evaluates the effects of Chloroquine phosphate on pain sensation in mice considering the fact tha
Chloroquine as s chemotherapic agent is known for its neurotoxici y effect. The mice were divided into three groups 
of 10 mice each. While group 1 as the control, 2 and 3 as the test groups and group 1 received 0.2ml physiological 
saline i.p. while test groups 2 and 3 received 10mg/k (human therapeutic dose) and 20ml/kg (pharmacological dose) 
of Chloroquine respectively. The tail flick and formalin tests were used to assess pain sensation. In the tail flick test, 
the latency of tail flick in group 2 and 3 were significantly lower compared to the control group in both phases, thus, 
showing an increase in pain sensation. In formalin tests, the frequency of right hind paw lick in group 2 was 
significantly higher compared to the control, representing an increase in pain sensitivity. The duration of hind paw 
lick was not significantly different among the groups. However, in phase 2, the duration of hind paw lick in group 2 
was higher than control, showing an increase in chronic pain sensitivity. Our results suggest that, Chloroquine 
phosphate increases pain sensation in mice. 
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______________________________________________ 
INTRODUCTION 
In human history, malaria, especially that caused by plasmodium falciparum is the world’s most devastating human 
parasitic infection. Malaria afflicts nearly 500 million people and causes some two million deaths each year 
(Breman,et at, 2001). It is widely distributed in the world, especially in the tropical Africa because of its ever 
increasing incidence of infection. Based on its wide spread  and trenchant effects on human affairs, more efforts are 
being made to find a more convenient drug with minial side effects for treatment of malaria. In view of this, 
chloroquine has been the drug of choice for malaria treatment. 
 
Chloroquine is a synthetic 4 amino –quinoline that has been th mainstay of antimalarial therapy until the recent 
appearance of drug resistant strains of P.falciparum (Mycek et al, 2000).It is commonly used in the chmotherapy of 
malaria fever and as anti-inflammatory agent in patients with rheumatoid arthritis or systemic lupus erythematosus 
(Onigbogi,et al, 2000). 
 
Chloroquine, however, has side effects among which are very comm n in black Africans (Ajayi,et al,1998). It 
should be used cautiously in patients with hepatic dysfunction and neurological or blood disorders. Also the drug 
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can cause electrocardiographic changes, since it has a quinidine like effect of inactivating sodium channels and 
preventing sodium influx, thus showing the rapid upstroke during phase 0 as well as decreases the slopof hase 4 
spontaneous depolarization (Mycek et al., 2000). 
 
Most of these side effects are infrequent or may be mild and tolerable at normal doses of the drug and they are 
reversible on withdrawal of the drug. For instance, corneal deposits of chloroquine may be asymptomatic or cause 
mild photophobia (Laurence et al, 1999). It has been reported that chloroquine causes blurred vision as one of its 
side effects, probably due to its effect on the latr l geniculation body of the thalamus (Ekanem and Caxton-Martins, 
2000). 
 
Amongst the known neurological side effects of chloroquine are psychosis, depression and dehlirum. It could 
depress invitroneuronal activity, perhaps, through inhibition of calcium channels as shown using the whole cell 
patch clamp method (O’shaughnessy et al., 2003). Also, Studies have showed that Chloroquine reduces locomotive 
activity and have a sedative effect (Musabayane et al., 1999; Etimita et al., 2005; Odo et al., 2007). 
 
However, in view of the neurologic and neurotoxic effects of chloroquine as reported, no report has been established 
on its effects on pain   behaviour. This study therefore, evaluates the effect of Chloroquine on pain  in mice. 
MATERIALS AND METHODS 
Experimental animal/ groups: The animals were bred in the animal house, department Pharmacology, University 
Calabar. The animals were kept in the animal house of department of Human Physiology, University of Calab r. 
The animals have access to rodent laboratory chow fr m laboratory depot at Okigwe in Abia State of Niger a and 
were fed for 3 weeks. The mice were used for the study after approval by the college ethical committee. 
 
For the experiment, a total of 30 thirty swiss mice of both sexes were used. The animals were randomly assigned 
into three groups (1, 2 and 3). All animals were raised under standard laboratory conditions and given free access to 
normal feed and clan tap water. Each group was made of ten (10) mice weighing 18-28g. 
 
Drug administration: Group 1 animals (control) were administered with 0.2ml normal saline intrapentoneally (i.p). 
Group 2 and 3 received 10mg/kg and 20mg/kg of chloroquine phosphate (Glaxo, Nigeria) (I.P) respectively, as safe 
dose having determined the LD50 as 367.18mg/kg. 10mg/kg of chloroquine served as the human therapeutic or low 
dose group while 20mg/kg served as the pharmacological or high dose group. The drug was obtained from 
University of Calabar Pharmacy and the administration lasted for 14 days. 
 
Determination of pain sensitivity: The tail flick nociceptive assay was used to assessed the effort of pain 
(D’Amour and Smith, 1941). In the tail flick test, the pain thresholds of mice are measured by using warm water as 
the tail flick of each mice. The latency was determined by placing the distal part of the tail (about 2.5cm) in the 
warm water (450c – 490c) in order to minimize the damage of the tail skin while the thermometer was constantly 
immersed into the hot water to determine the temperature. A stopwatch was set and usually started immediately the 
tail of the mouse was immersed into the hot water a 49oc. The stopwatch was stopped exactly when the mouse 
flicked its tail from the hot water. The time was recorded as latency of tail flick. The experiment was repeated after 
one (1) hour for each mouse in the control and test groups. 
 
On the other hand, the formalin test was performed on the mice. The animals were injected with 0.2ml of 25% 
formalin solution on their right hind paw with a syringe and needle according to Hunskwar and Hole (1987). After 
the formalin administration, the animals were isolated and observed for the first 5 minutes before it was taken back 
to the observation box. Each animal was then returnd to its cage and allowed for thirty (30) minutes b fore it was 
taken back to the observation box to be re-observed for another 5 minutes. 
 
Sample collection: The behaviours scored during the pain test include: Rearing frequency, grooming frequency, 
grooming duration, Frequency of right hind lick/scrat h, frequency of right hind paw attention, duration of attention. 
 
Statistical Analysist: Data were then analysed using one-way analysis of variance (ANOVA) followed by post hoc 
student´s t-test. Data were presented as means ± Standard error of the mean (SEM) and were regarded as stati tically 
significant at a p<0.05. 
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RESULTS 
The results from the tail flick test showed that in r al 1, both human therapeutic (Low) and pharmacological (High) 
doses were significantly (p<0.001) lower compared to the control. However, pharmacological dose was significantly 
(p<0.01) higher compared to therapeutic group 
 
In trial 2, human therapeutic and pharmacological doses were significantly (p<0.001 and p<0.01) lower compared to 
control .While pharmacological dose was significantly (p<0.01) higher compared to the human therapeutic dose. 
 
Latency of tail flick test in trial i & ii (Fig. 1): 
Latency of tail flick is the time taken for the animal to flick its tail from the hot water. 
 
The results from the tail flick test showed that in trial I, the mean latency of tail flick were 21.36 + 2.20sec for 
control, 9.17 + 0.89sec for therapeutic and 13.43 + 0.75sec for pharmacological group(s). From the result, both 
human therapeutic and pharmacological groups were significantly (P<0.001) higher compared to the contrl. Also, 
pharmacological group was significantly (P<0.01) higher compared to the therapeutic group. 
 
In trial II, the mean latency of tail flick were 25.63 + 2.16sec for control, 13.52 + 0.98sec for therapeutic group and 
19.28 + 1.33sec for pharmacological group. The result shows that therapeutic group was significantly (P<0.01) 
lower compared to the control. While the pharmacological group was significantly (P<0.01) higher compared to the 
control group and significantly higher than the therapeutic group (P<0.01). 
 
Behaviours scored in the observation box of formalin test. 
 
Frequency of right hind paw lick (Fig 2): The frequency of right hind paw in the control group with mean value of 
8.40± 1.20/5min, and therapeutic group had 16.80±2.67/5min, while the pharmacological group was 
11.20±1.39/5min,in the acute phase of the test. In chronic phase, the control was 1.20±0.58/5min, 6.25±1.03 for 
therapeutic group while 3.00±0.70 for pharmacological group in the phase 2. 
 
The result show that the therapeutic group was significa tly (p<0.001) and (p<0.001) higher compared to the control 
in phase 1 and 2 respectively. While pharmacological group was not significant compared to the control gr up, but 
was significantly (p<0.05) and (p<0.01) lower compared to the therapeutic group in phase 1 and 2 respectively. 
 
Duration of right hind paw lick (Fig 3): In acute phase, the duration of hind paw lick were 32.92±6.53 sec for 
control, 52.72±12.01sec for therapeutic and 34.00±5.8sec for pharmacological groups. From the result, there was no 
significant difference among the groups. In chronic phase, the duration of right hind paw lick mean values were 
3.04±1.34sec,for control,14.70±2.76sec,for therapeutic and 5.72±2.23sec,for pharmacological groups. Result shows 
that therapeutic group was significantly (p<0.001) higher compared to the control group, While pharmacological 
group was not significant compared to the control group but was significantly(p<0.01) lower compared to the 
therapeutic group. 
 
Frequency of right hind paw attention (Fig 4): In acute phase, the mean values were:13.00±1.51/5min, for 
control, 24.80±3.6/5min for therapeutic and 16.80±3.33/5min pharmacological group(s). From the result, therapeutic 
was significantly (p<0.01) higher compared to the control and the therapeutic groups. In chronic phase, th  mean 
values were:1.80±0.66/5min, for control, 2.60±0.50/5min,for therapeutic and 1.50±0.50/5min, for pharmacological 
group(s).The result shows that there was no significant difference among the groups. 
 
Frequency of rearing (Fig. 5): In acute phase, the mean values were:7.00±1.41/5min, for control, 1.40±0.97/5min, 
for therapeutic and 2.40±1.28/5min,for pharmacological group(s).The result shows that both therapeutic and 
pharmacological groups were significantly (p<0.01) lower compared to the control group. There was no significant 
difference between the test groups. In chronic phase, the mean values were 3.60±1.07/5min, for control, 
1.60±0.37/5min for therapeutic, 2.40±0.96/5min, for pharmacological group(s).From the result, there was no 
significant difference among the groups. 
 
Frequency of grooming (Fig. 6): In acute phase, the mean values were 3.80±0.86/5min,for control, 
1.00±0.44/5min,for therapeutic and 2.80±0.66/5min for pharmacological group(s).The result shows that terapeutic 
group was significantly (p<0.01) lower compared to the control. The pharmacological group was not significant 
compared to the control group and therapeutic group. In chronic phase, the mean values were: 5.4±1.20/5min 
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control,2.80±0.73/5min therapeutic group and 5.40±1.43/5min for pharmacological group.The result shows no 
significant difference among the groups. 
 
Duration of grooming (Fig. 7): In acute phase, the mean values were 8.88±2.83 for control, 2.00±1.02sec 
therapeutic and 7.90±1.41 sec for pharmacological group(s). From the result, therapeutic group was significantly 
(P<0.01) lower compared to the control group while pharmacological group was not significant compared to the 
control but was significantly (p<0.05) higher compared to the therapeutic group. 
 
In chronic phase, the mean values were 12.24±2.77sec for control, 6.58±2.14sec for therapeutic group and 































Fig. 1: Comparison of latency of tail flick in the tail flick test between mice treated with therapeutic and 
pharmacological doses of Chloroquine with the control. 






























Fig. 2: Comparison of frequency of hind paw lick during the first and second phases of the formalin test in 
mice treated with therapeutic and pharmacological doses of Chloroquine with the control. 






































Fig. 3: Comparison of duration of hind paw lick during the first and second phases of the formalin test in 
mice treated with therapeutic and pharmacological doses of Chloroquine with the control. 






































Fig. 4: Comparison of frequency of hind paw attention during the first and second phases of the formalin test 
in mice treated with therapeutic and pharmacological doses of Chloroquine with the control. 



































Fig. 5: Comparison of frequency of rearing during the first and second phases of the formalin test in mice 
treated with therapeutic and pharmacological doses of Chloroquine with the control. 
NS=Not significant compared to control; **=p< 0.01 compared to control 
 
 




































Fig. 6: Comparison of frequency of grooming during the first and second phases of the formalin test in mice 
treated with therapeutic and pharmacological doses of Chloroquine with the control. 


































Fig. 7: Comparison of duration of hind paw grooming during the first and second phases of the formalin test 
in mice treated with therapeutic and pharmacological doses of Chloroquine with the control. 




Tail flick is a process that involves radiant heat which is applied on the animals tail when the animal feels 
discomfort, there is a sudden tail movement (tail flick) as designed by D´Amour and Smith (1941). In the present 
experiment, the tail flick test showed significant differences (Fig 1) among the groups (1, 2 and 3) with the test 
groups (2 and 3) having low latency of tail flick ind cating increase in pain sensitivity. 
 
The formalin test was another model used in testing pain sensation in animals as designed by Hunskaar and Hole 
(1987).The formalin test is made of two phases, the acute phase and the chronic phase. In the case of th  formalin 
test in the present experiment, the frequency and duration of hind paw lick, frequency and duration of hind paw 
attention were used to assessed the change in perception of pain sensation in the animals. Mice which feel more pain 
will exhibit more of these behaviours. The frequency and duration of hind paw lick and hind paw attentio  in the test 
groups were significantly higher compared to the control, thus, indicating increased in pain. Also, a decrease in 
frequency of rearing and frequency and duration of gr oming shows an increased in pain sensation. 
 
This study reveals that there was a significant increase in pain sensitivity both during the acute phase nd chronic 
phase of pain in the experimental groups compared with the control. This increase may be due to the rel ase of 
chemical pain excitants such as bradykinin, serotonin, histamine, acetycholine, prostaglandin and proteoly ic 
enzymes which stimulate chemosensitive free nerve endings (pain receptors) and excite pain by making their 
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Also, experimental findings have indicated that substance P and bradykinins participate in early phase while 
histamine, serotonin and prostaglandins are involved in the late phase (Shibata et al., 1989). Moreso, it probably 
enhances the opening of the TRPV1(transient receptor potential vanilloid receptor 1) a ligand –gated cation receptor 
which is permeable to Na+, Ca+ and other cation causing depolarization and initiation of action potential (Wang and 
Woolf,2005). However, the mechanism by which C loroquine increase pain sensitivity in mice is not certain. 
 
In conclusion, the administration of Chloroquine phosphate may induce pain sensations in a dose dependent manner. 
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